Nancy Leung
Alice Ho Miu Ling Nethersole Hospital
120 Papers
2K Citations
Nancy Leung is an academic researcher from Alice Ho Miu Ling Nethersole Hospital. The author has contributed to research in topics: Hepatitis B & Lamivudine. The author has an hindex of 46, co-authored 120 publications. Previous affiliations of Nancy Leung include The Chinese University of Hong Kong & University College London.
Chat about Author
Papers
Long-term safety of lamivudine treatment in patients with chronic hepatitis B.
Anna S.F. Lok,Ching-Lung Lai,Nancy Leung,Guang Bi Yao,Zhen Yu Cui,Eugene R. Schiff,Jules L. Dienstag,E. Jenny Heathcote,Nancy R. Little,Dorothea A. Griffiths,Stephen D. Gardner,Mary Castiglia +11 more
TL;DR: It is demonstrated that lamivudine treatment for up to 6 years has an excellent safety profile in patients with HBeAg-positive compensated liver disease, but patients with long-standing lamivUDine-resistant mutations may experience worsening liver disease.
842
Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B
Ching-Lung Lai,Jules L. Dienstag,Eugene R. Schiff,Nancy Leung,Mark Atkins,Christine M. Hunt,Nathaniel A. Brown,Mary Woessner,Richard Boehme,Lynn D. Condreay +9 more
TL;DR: Patients with YMDD variants losing clinical response with a significant increase in the HBV DNA and ALT levels may require additional therapy.
Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab
Winnie Yeo,Tung C. Chan,Nancy Leung,Wai Y. Lam,Frankie Mo,Miu Ting Chu,Henry Lik-Yuen Chan,Edwin P. Hui,Kenny I.K. Lei,Tony Mok,Paul K.S. Chan +10 more
TL;DR: Close monitoring until at least 6 months after anticancer therapy is required, with an alternative approach of prophylactic antiviral therapy to prevent this potentially fatal condition.
650
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
Yun Fan Liaw,Edward Gane,Nancy Leung,Stefan Zeuzem,Yuming Wang,Ching-Lung Lai,E. Jenny Heathcote,Michael P. Manns,Natalie Bzowej,Junqi Niu,Steven Han,Seong Gyu Hwang,Yilmaz Cakaloglu,Myron J. Tong,George V. Papatheodoridis,Yagang Chen,Nathaniel A. Brown,Efsevia Albanis,Karin Galil,Nikolai V. Naoumov +19 more
TL;DR: Telbvudine is superior to lamivudine in treating patients with chronic hepatitis B over a 2-year period, and multivariate logistic regression analyses identified telbivUDine treatment, among other variables, as an independent predictor of better week 104 outcomes.
599
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update.
Yun-Fan Liaw,Nancy Leung,Richard Guan,George K. K. Lau,Ismail Merican,Geoff McCaughan,Edward Gane,Jia-Horng Kao,Masao Omata +8 more
TL;DR: A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update.